共 106 条
[1]
Bookman M(2005)Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic Int J Gynecol Cancer 15 12-17
[2]
Briasoulis E(2000)Phase I trial of 6-h infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European organization for research and treatment of cancer early clinical studies group J Clin Oncol 18 3535-3544
[3]
Judson I(2003)Glufosfamide administered using a 1-h infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group Eur J Cancer 39 2334-2340
[4]
Pavlidis N(1979)Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sulfosfamide Arzneimittelforschung 29 659-661
[5]
Beale P(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-2413
[6]
Wanders J(2005)Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer Cancer Chemother Pharmacol 56 563-568
[7]
Groot Y(2004)Glufosfamide administered by 1-h infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group Eur J Cancer 40 667-672
[8]
Veerman G(2006)High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer Cancer Chemother Pharmacol 57 640-646
[9]
Schuessler M(1997)Gemcitabine: a cytidine analogue active against solid tumors Am J Health Syst Pharm 54 162-170
[10]
Niebch G(2004)Single-agent gemcitabine in the treatment of advanced breast cancer Clin Breast Cancer 4 S101-S106